Rankings
▼
Calendar
RYTM Q2 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RYTM
Rhythm Pharmaceuticals, Inc.
$6B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$49M
+66.8% YoY
Gross Profit
$43M
88.6% margin
Operating Income
-$45M
-93.4% margin
Net Income
-$47M
-96.1% margin
EPS (Diluted)
$-0.75
QoQ Revenue Growth
+48.3%
Cash Flow
Operating Cash Flow
-$23M
Free Cash Flow
-$23M
Stock-Based Comp.
$16M
Balance Sheet
Total Assets
$373M
Total Liabilities
$385M
Stockholders' Equity
-$12M
Cash & Equivalents
$136M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$49M
$29M
+66.8%
Gross Profit
$43M
$26M
+64.4%
Operating Income
-$45M
-$40M
-11.9%
Net Income
-$47M
-$32M
-44.5%
Revenue Segments
Product
$49M
100%
Geographic Segments
Non-US
$17M
100%
← FY 2025
All Quarters
Q3 2025 →